Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lindall Perry

MOHS-Micrographic Surgery Columbia, MO Medical Doctor

NPI 1720036072 CMS profile 78228

401 Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$10,731

471 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindall Perry of Columbia, MO is reported in the CMS Open Payments database as having received $10,731 across 471 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,567 63
2024 General $1,766 82
2023 General $2,299 103
2022 General $1,807 87
2021 General $1,102 56
2020 General $448 23
2019 General $1,741 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindall Perry
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Lindall Perry were reported at $1,567. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Lindall Perry MOHS-Micrographic Surgery median Middle half National median
2019 $1,741 $316 $106–$785 $163
2020 $448 $162 $68–$412 $114
2021 $1,102 $243 $87–$654 $132
2022 $1,807 $300 $102–$887 $149
2023 $2,299 $364 $125–$1,010 $160
2024 $1,766 $445 $142–$1,108 $164
2025 $1,567 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,501 159 payments
  2. Novartis Pharmaceuticals Corporation $1,888 90 payments
  3. Janssen Biotech, Inc. $608 34 payments
  4. Regeneron Healthcare Solutions, Inc. $572 21 payments
  5. Lilly USA, LLC $512 26 payments
  6. UCB, Inc. $486 12 payments
  7. Genzyme Corporation $349 7 payments
  8. E.R. Squibb & Sons, L.L.C. $340 15 payments
  9. Janssen Scientific Affairs, LLC $266 3 payments
  10. Pfizer Inc. $256 12 payments
  11. Other $1,952 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,723 470 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,653 76 payments
  2. COSENTYX Dermatology $1,032 48 payments
  3. RINVOQ $1,028 49 payments
  4. HUMIRA $720 33 payments
  5. TREMFYA $716 26 payments
  6. COSENTYX Immunology $576 30 payments
  7. Bimzelx $403 9 payments
  8. DUPIXENT $390 11 payments
  9. TALTZ $381 23 payments
  10. SOTYKTU $340 15 payments
  11. Other $5,030 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

748

Median for Dermatology: 534

Drug cost

$173,458

Median for Dermatology: $67,151

Branded share of claims

16.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $120,491
Dupixent Pen Dupilumab Brand 11 $42,748
Clobetasol Propionate Generic 51 $2,892
Acitretin Generic 13 $1,754
Cephalexin Generic 289 $1,201
Metronidazole Generic 18 $972
Triamcinolone Acetonide Generic 89 $764
Mupirocin Generic 75 $649
Ondansetron Odt Ondansetron Brand 13 $588
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 66 $380

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$1,301,171

Of which drugs: $102,538

Medicare patients

2,470

Average age 76

Services billed

15,989

1,226 women, 1,244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 26%
Ischemic heart disease 25%
Atrial fibrillation 19%
Chronic kidney disease 17%
Cancer 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 30 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $349
$349 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $337
$337 14 —
Bimzelx
  • UCB, Inc. $188
$188 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $178
$178 — —
RINVOQ
  • AbbVie, Inc. $123
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

471 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record